双刺激响应生物化聚合物-药物合物用于双药物输送
Desoshree Ghosh1, Afruja Khan2, Sagar Bag1
1Polymer Research Centre and Centre for Advanced Functional Materials, Department of Chemical Sciences, Indian Institute of Science Education and Research Kolkata, Mohanpur - 741246, Nadia, West Bengal, India. p_de@iiserkol.ac.in.
Journal of materials chemistry. B
|October 23, 2024
概括
这项研究开发了一种双刺激响应的聚合物-药物合物 (DP2@DOX),可释放抗癌药物,以应对活性氧物种 (ROS) 和酶. 生物化增强了向传递和在癌细胞中的协同效果.
科学领域:
- 生物医学工程 生物医学工程
- 材料科学 材料科学 材料科学
- 纳米技术纳米技术
背景情况:
- 刺激响应的聚合物药物合物提供了先进的治疗效益,如控制释放和降低毒性.
- 开发有针对性的药物输送系统对于有效的癌症治疗至关重要.
研究的目的:
- 为了创建一个双刺激响应,自组装的聚合物-药物合物 (DP2@DOX) 用于向癌症治疗.
- 为了研究药物释放机制和结合物的细胞吸收.
- 为了评估结合剂在癌细胞中的协同抗癌功效.
主要方法:
- 合成了一种生物化聚合物-药物联合体 (DP2),载有多克索鲁比 (DOX).
- 通过反应性氧物种 (ROS) 和酶触发的ambucil (CBL) 和DOX的研究释放.
- 评估生物受体阳性 (HeLa) 和阴性 (HEK 293T) 细胞的细胞吸收和抗癌活性,使用共聚焦显微镜和流细胞计.
主要成果:
- 该DP2@DOX结合体证明了CBL和DOX的双刺激反应释放.
- 与HEK 293T细胞相比,生物化显著增强了HeLa细胞的细胞吸收.
- 由于药物递送的增强,在HeLa细胞中观察到协同作用的抗癌活性.
结论:
- 开发的自组装聚合物-药物联体是一种有前途的双刺激响应药物递送载体.
- 生物化增强了向癌细胞的吸收和治疗疗效.
- 这个平台代表了先进的癌症治疗方法的下一代方法.
更多相关视频
14:20Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
16.7K
10:15The Use of the Ex Vivo Chandler Loop Apparatus to Assess the Biocompatibility of Modified Polymeric Blood Conduits
Published on: August 20, 2014
11.6K
相关概念视频
01:16Drug Biotransformation: Overview
2.3K
Pharmaceutical substances known as xenobiotics are predominantly lipophilic and nonionized. This enables them to permeate lipid bilayers, such as cell membranes, and interact with intracellular target receptors. Lipophilic drugs have an advantage in crossing biological barriers and reaching their intended sites of action. However, lipophilic drugs often have a restricted capacity for renal expulsion or elimination from the body. When these drugs enter the kidneys and undergo glomerular...
2.3K
01:14Drug Metabolism: Phase II Reactions
3.7K
Phase II reactions are essential for the detoxification and elimination of drugs from the body. These reactions involve the conjugation of parent drugs or their phase I metabolites with endogenous molecules, resulting in more hydrophilic drug conjugates. The primary conjugation reactions in this phase are sulfation and glucuronidation. Both sulfation and glucuronidation typically produce biologically inactive metabolites. However, in some cases involving prodrugs, active metabolites may be...
3.7K